After a product receives marketing authorization, its regulatory journey is far from over. Post-approval lifecycle management is an essential, ongoing activity that ensures products remain compliant, competitive, and continuously improved throughout their commercial lifespan.
ReguLinx provides comprehensive post-approval regulatory support — managing changes to manufacturing processes, sites, specifications, analytical methods, formulations, and more — across all major global markets.
Post-Approval Variations and Amendments
CBE-0 / CBE-30 / PAS (US FDA) Changes to an approved NDA or ANDA are submitted to FDA as one of three change types: Changes Being Effected immediately (CBE-0), Changes Being Effected within 30 days (CBE-30), or Prior Approval Supplements (PAS). ReguLinx prepares and submits these change supplements with complete CMC documentation support.
Type IA / Type IB / Type II Variations (EMA) Post-approval changes to EU Marketing Authorizations are classified as Type IA (minor administrative), Type IB (minor technical), or Type II (major changes). We manage the full variation lifecycle — from change classification through to final EMA approval.
Minor Change Notifications (MCN) and Partial Change Notifications (PCN) — Japan Japan has its own post-approval change management framework. ReguLinx handles MCN and PCN submissions to PMDA, including preparation of all required documentation in compliance with Japanese regulatory standards.
Post Approval Change Management Protocols (PACMP) PACMP is an FDA mechanism that allows sponsors to pre-define a set of changes and the studies required to support them, streamlining future post-approval submissions. ReguLinx develops PACMPs to help clients efficiently manage anticipated product and process changes over the product lifecycle.
Manufacturing Site Transfers
Transferring drug substance or drug product manufacturing from one site to another requires careful regulatory management. A site transfer affects CMC documentation, potentially triggering major variations or prior approval supplements depending on the jurisdiction.
ReguLinx manages the full regulatory component of manufacturing site transfers — reviewing existing documentation, preparing updated CMC sections, and filing appropriate change applications across all relevant markets simultaneously.
Response to Health Authority Questions — Post Approval
Health authority questions on post-approval submissions require the same scientific rigor and urgency as pre-approval responses. Our team provides rapid, compliant responses to agency queries across FDA, EMA, PMDA, and other health authorities — protecting your commercial operations and market access.